Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 152

1.

Late relapses in diffuse large B-cell lymphoma: where to move next?

Nijland M, Kluin-Nelemans HC.

Leuk Lymphoma. 2020 Feb 4:1-2. doi: 10.1080/10428194.2020.1716224. [Epub ahead of print] No abstract available.

PMID:
32013680
2.

WEE1 inhibition synergizes with CHOP chemotherapy and radiation therapy through induction of premature mitotic entry and DNA damage in diffuse large B-cell lymphoma.

de Jong MRW, Langendonk M, Reitsma B, Herbers P, Lodewijk M, Nijland M, van den Berg A, Ammatuna E, Visser L, van Meerten T.

Ther Adv Hematol. 2020 Jan 20;11:2040620719898373. doi: 10.1177/2040620719898373. eCollection 2020.

3.

Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide: results of a multicenter HOVON phase II trial.

Chamuleau MED, Burggraaff CN, Nijland M, Bakunina K, Mous R, Lugtenburg PJ, Dierickx D, van Imhoff GW, Vermaat JSP, Marijt EAF, Visser O, Mandigers C, Bilgin YM, Beeker A, Durian MF, van Rees B, Bohmer LH, Tick LW, Boersma RS, Snijders TJF, Schouten HC, Koene HR, de Jongh E, Hijmering N, Diepstra A, van den Berg A, Arens AIJ, Huijbregts J, Hoekstra O, Zijlstra JM, de Jong D, Kersten MJ.

Haematologica. 2019 Dec 19. pii: haematol.2019.238162. doi: 10.3324/haematol.2019.238162. [Epub ahead of print]

4.

Heterogeneous Pattern of Dependence on Anti-Apoptotic BCL-2 Family Proteins upon CHOP Treatment in Diffuse Large B-Cell Lymphoma.

de Jong MRW, Langendonk M, Reitsma B, Nijland M, van den Berg A, Ammatuna E, Visser L, van Meerten T.

Int J Mol Sci. 2019 Nov 30;20(23). pii: E6036. doi: 10.3390/ijms20236036.

5.

The OncoLifeS data-biobank for oncology: a comprehensive repository of clinical data, biological samples, and the patient's perspective.

Sidorenkov G, Nagel J, Meijer C, Duker JJ, Groen HJM, Halmos GB, Oonk MHM, Oostergo RJ, van der Vegt B, Witjes MJH, Nijland M, Havenga K, Maduro JH, Gietema JA, de Bock GH.

J Transl Med. 2019 Nov 14;17(1):374. doi: 10.1186/s12967-019-2122-x.

6.

WEE1 Inhibition Enhances Anti-Apoptotic Dependency as a Result of Premature Mitotic Entry and DNA Damage.

de Jong MRW, Langendonk M, Reitsma B, Herbers P, Nijland M, Huls G, van den Berg A, Ammatuna E, Visser L, van Meerten T.

Cancers (Basel). 2019 Nov 7;11(11). pii: E1743. doi: 10.3390/cancers11111743.

7.

Ibrutinib-associated invasive fungal diseases in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: An observational study.

Ruchlemer R, Ben-Ami R, Bar-Meir M, Brown JR, Malphettes M, Mous R, Tonino SH, Soussain C, Barzic N, Messina JA, Jain P, Cohen R, Hill B, Mulligan SP, Nijland M, Herishanu Y, Benjamini O, Tadmor T, Okamoto K, Arthurs B, Gottesman B, Kater AP, Talha M, Eichhorst B, Korem M, Bogot N, De Boer F, Rowe JM, Lachish T.

Mycoses. 2019 Dec;62(12):1140-1147. doi: 10.1111/myc.13001. Epub 2019 Oct 22.

PMID:
31520441
8.

Diagnostic performance of FDG-PET/CT of post-transplant lymphoproliferative disorder and factors affecting diagnostic yield.

Montes de Jesus FM, Kwee TC, Kahle XU, Nijland M, van Meerten T, Huls G, Dierckx RAJO, Rosati S, Diepstra A, van der Bij W, Verschuuren EAM, Glaudemans AWJM, Noordzij W.

Eur J Nucl Med Mol Imaging. 2020 Mar;47(3):529-536. doi: 10.1007/s00259-019-04481-7. Epub 2019 Aug 24.

PMID:
31444510
9.

CD47 Expression Defines Efficacy of Rituximab with CHOP in Non-Germinal Center B-cell (Non-GCB) Diffuse Large B-cell Lymphoma Patients (DLBCL), but Not in GCB DLBCL.

Bouwstra R, He Y, de Boer J, Kooistra H, Cendrowicz E, Fehrmann RSN, Ammatuna E, Zu Eulenburg C, Nijland M, Huls G, Bremer E, van Meerten T.

Cancer Immunol Res. 2019 Oct;7(10):1663-1671. doi: 10.1158/2326-6066.CIR-18-0781. Epub 2019 Aug 13.

PMID:
31409608
10.

Relationship between semiquantitative 18F-fluorodeoxyglucose positron emission tomography metrics and necrosis in classical Hodgkin lymphoma.

Kahle XU, Montes de Jesus FM, Kwee TC, van Meerten T, Diepstra A, Rosati S, Glaudemans AWJM, Noordzij W, Plattel WJ, Nijland M.

Sci Rep. 2019 Jul 30;9(1):11073. doi: 10.1038/s41598-019-47453-5.

11.

MYD88 mutations identify a molecular subgroup of diffuse large B-cell lymphoma with an unfavorable prognosis.

Vermaat JS, Somers SF, de Wreede LC, Kraan W, de Groen RAL, Schrader AMR, Kerver ED, Scheepstra CG, Berenschot H, Deenik W, Wegman J, Broers R, de Boer JD, Nijland M, van Wezel T, Veelken H, Spaargaren M, Cleven AH, Kersten MJ, Pals ST.

Haematologica. 2020 Jan 31;105(2):424-434. doi: 10.3324/haematol.2018.214122. Print 2020.

12.

Tumour necrosis as assessed with 18F-FDG PET is a potential prognostic marker in diffuse large B cell lymphoma independent of MYC rearrangements.

Kahle XU, Hovingh M, Noordzij W, Seitz A, Diepstra A, Visser L, van den Berg A, van Meerten T, Huls G, Boellaard R, Kwee TC, Nijland M.

Eur Radiol. 2019 Nov;29(11):6018-6028. doi: 10.1007/s00330-019-06178-9. Epub 2019 Apr 26.

13.

Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study.

Bromberg JEC, Issa S, Bakunina K, Minnema MC, Seute T, Durian M, Cull G, Schouten HC, Stevens WBC, Zijlstra JM, Baars JW, Nijland M, Mason KD, Beeker A, van den Bent MJ, Beijert M, Gonzales M, de Jong D, Doorduijn JK.

Lancet Oncol. 2019 Feb;20(2):216-228. doi: 10.1016/S1470-2045(18)30747-2. Epub 2019 Jan 7.

PMID:
30630772
14.

Mutational Evolution in Relapsed Diffuse Large B-Cell Lymphoma.

Nijland M, Seitz A, Terpstra M, van Imhoff GW, Kluin PM, van Meerten T, Atayar Ç, van Kempen LC, Diepstra A, Kok K, van den Berg A.

Cancers (Basel). 2018 Nov 20;10(11). pii: E459. doi: 10.3390/cancers10110459.

15.

Performance of advanced imaging modalities at diagnosis and treatment response evaluation of patients with post-transplant lymphoproliferative disorder: A systematic review and meta-analysis.

Montes de Jesus FM, Kwee TC, Nijland M, Kahle XU, Huls G, Dierckx RAJO, van Meerten T, Gheysens O, Dierickx D, Vergote V, Noordzij W, Glaudemans AWJM.

Crit Rev Oncol Hematol. 2018 Dec;132:27-38. doi: 10.1016/j.critrevonc.2018.09.007. Epub 2018 Sep 19.

16.

Phase I dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical Hodgkin lymphoma: The HOVON/LLPC Transplant BRaVE study.

Hagenbeek A, Mooij H, Zijlstra J, Lugtenburg P, van Imhoff G, Nijland M, Tonino S, Hutchings M, Spiering M, Liu R, van Tinteren H, Kersten MJ.

Haematologica. 2019 Apr;104(4):e151-e153. doi: 10.3324/haematol.2018.196899. Epub 2018 Oct 31. No abstract available.

17.

CO2-Switchable Solvents as Entrainer in Fluid Separations.

Schuur B, Nijland M, Blahušiak M, Juan A.

ACS Sustain Chem Eng. 2018 Aug 6;6(8):10429-10435. doi: 10.1021/acssuschemeng.8b01771. Epub 2018 Jun 29.

18.

Feasibility and efficacy of addition of individualized-dose lenalidomide to chlorambucil and rituximab as first-line treatment in elderly and FCR-unfit patients with advanced chronic lymphocytic leukemia.

Kater AP, van Oers MHJ, van Norden Y, van der Straten L, Driessen J, Posthuma WFM, Schipperus M, Chamuleau MED, Nijland M, Doorduijn JK, Van Gelder M, Hoogendoorn M, De Croon F, Wittebol S, Kerst JM, Marijt EWA, Raymakers RAP, Schaafsma MR, Dobber JA, Kersting S, Levin MD; HOVON CLL study group.

Haematologica. 2019 Jan;104(1):147-154. doi: 10.3324/haematol.2018.193854. Epub 2018 Aug 16.

19.

Maternal activity, anxiety, and protectiveness during moderate nutrient restriction in captive baboons (Papio sp.).

Light LEO, Bartlett TQ, Poyas A, Nijland MJ, Huber HF, Li C, Keenan K, Nathanielsz PW.

J Med Primatol. 2018 May 11. doi: 10.1111/jmp.12350. [Epub ahead of print]

20.

Anti-citrullinated protein antibody response after primary EBV infection in kidney transplant patients.

Kraal LJN, Nijland ML, Germar KL, Baeten DLP, Ten Berge IJM, Fehres CM.

PLoS One. 2018 May 10;13(5):e0197219. doi: 10.1371/journal.pone.0197219. eCollection 2018.

21.

Lactate dehydrogenase levels and 18F-FDG PET/CT metrics differentiate between mediastinal Hodgkin's lymphoma and primary mediastinal B-cell lymphoma.

Alkhawtani RHM, Noordzij W, Glaudemans AWJM, van Rijn RS, van der Galiën HT, Balink H, Nijland M, Adams HJA, Huls G, van Meerten T, Kwee TC.

Nucl Med Commun. 2018 Jun;39(6):572-578. doi: 10.1097/MNM.0000000000000840.

PMID:
29672465
22.

The non-human primate kidney transcriptome in fetal development.

Spradling-Reeves KD, Glenn JP, Lange KJ, Kuhn N, Coalson JJ, Nijland MJ, Li C, Nathanielsz PW, Cox LA.

J Med Primatol. 2018 Jun;47(3):157-171. doi: 10.1111/jmp.12340. Epub 2018 Mar 30.

23.

Nonhuman primate breath volatile organic compounds associate with developmental programming and cardio-metabolic status.

Bishop AC, Libardoni M, Choudary A, Misra B, Lange K, Bernal J, Nijland M, Li C, Olivier M, Nathanielsz PW, Cox LA.

J Breath Res. 2018 May 14;12(3):036016. doi: 10.1088/1752-7163/aaba84.

24.

High prevalence of MYD88 and CD79B mutations in intravascular large B-cell lymphoma.

Schrader AMR, Jansen PM, Willemze R, Vermeer MH, Cleton-Jansen AM, Somers SF, Veelken H, van Eijk R, Kraan W, Kersten MJ, van den Brand M, Stevens WBC, de Jong D, Abdul Hamid M, Tanis BC, Posthuma EFM, Nijland M, Diepstra A, Pals ST, Cleven AHG, Vermaat JSP.

Blood. 2018 May 3;131(18):2086-2089. doi: 10.1182/blood-2017-12-822817. Epub 2018 Mar 7. No abstract available.

PMID:
29514783
25.

Combined PD-1 and JAK1/2 inhibition in refractory primary mediastinal B-cell lymphoma.

Nijland M, van Meerten T, Seitz A, Huls G, Kibbelaar R, Visser L, van den Berg A, Diepstra A.

Ann Hematol. 2018 May;97(5):905-907. doi: 10.1007/s00277-018-3233-9. Epub 2018 Jan 11. No abstract available.

PMID:
29327077
26.

Spectral and temporal electroencephalography measures reveal distinct neural networks for the acquisition, consolidation, and interlimb transfer of motor skills in healthy young adults.

Veldman MP, Maurits NM, Nijland MAM, Wolters NE, Mizelle JC, Hortobágyi T.

Clin Neurophysiol. 2018 Feb;129(2):419-430. doi: 10.1016/j.clinph.2017.12.003. Epub 2017 Dec 20.

PMID:
29304417
27.

Clinicopathological characteristics of T-cell non-Hodgkin lymphoma arising in patients with immunodeficiencies: a single-center case series of 25 patients and a review of the literature.

Nijland ML, Koens L, Pals ST, Berge IJMT, Bemelman FJ, Kersten MJ.

Haematologica. 2018 Mar;103(3):486-496. doi: 10.3324/haematol.2017.169987. Epub 2017 Dec 21.

28.

Treatment of sporadic Burkitt lymphoma in adults, a retrospective comparison of four treatment regimens.

Oosten LEM, Chamuleau MED, Thielen FW, de Wreede LC, Siemes C, Doorduijn JK, Smeekes OS, Kersten MJ, Hardi L, Baars JW, Demandt AMP, Stevens WBC, Nijland M, van Imhoff GW, Brouwer R, Uyl-de Groot CA, Kluin PM, de Jong D, Veelken H.

Ann Hematol. 2018 Feb;97(2):255-266. doi: 10.1007/s00277-017-3167-7. Epub 2017 Dec 6.

29.

Combined loss of HLA I and HLA II expression is more common in the non-GCB type of diffuse large B cell lymphoma.

van der Meeren LE, Visser L, Diepstra A, Nijland M, van den Berg A, Kluin PM.

Histopathology. 2018 Apr;72(5):886-888. doi: 10.1111/his.13445. Epub 2018 Jan 29. No abstract available.

PMID:
29194719
30.

Relapse in stage I(E) diffuse large B-cell lymphoma.

Nijland M, Boslooper K, van Imhoff G, Kibbelaar R, Joosten P, Storm H, van Roon EN, Diepstra A, Kluin-Nelemans HC, Hoogendoorn M.

Hematol Oncol. 2018 Apr;36(2):416-421. doi: 10.1002/hon.2487. Epub 2017 Oct 30.

31.

Prognostic Model to Predict Post-Autologous Stem-Cell Transplantation Outcomes in Classical Hodgkin Lymphoma.

Chan FC, Mottok A, Gerrie AS, Power M, Nijland M, Diepstra A, van den Berg A, Kamper P, d'Amore F, d'Amore AL, Hamilton-Dutoit S, Savage KJ, Shah SP, Connors JM, Gascoyne RD, Scott DW, Steidl C.

J Clin Oncol. 2017 Nov 10;35(32):3722-3733. doi: 10.1200/JCO.2017.72.7925. Epub 2017 Sep 12.

PMID:
28898161
32.

MYC expression and translocation analyses in low-grade and transformed follicular lymphoma.

Aukema SM, van Pel R, Nagel I, Bens S, Siebert R, Rosati S, van den Berg E, Bosga-Bouwer AG, Kibbelaar RE, Hoogendoorn M, van Imhoff GW, Kluin-Nelemans HC, Kluin PM, Nijland M.

Histopathology. 2017 Dec;71(6):960-971. doi: 10.1111/his.13316. Epub 2017 Oct 17.

PMID:
28730642
33.

HLA dependent immune escape mechanisms in B-cell lymphomas: Implications for immune checkpoint inhibitor therapy?

Nijland M, Veenstra RN, Visser L, Xu C, Kushekhar K, van Imhoff GW, Kluin PM, van den Berg A, Diepstra A.

Oncoimmunology. 2017 Mar 3;6(4):e1295202. doi: 10.1080/2162402X.2017.1295202. eCollection 2017.

34.

Tuning of large piezoelectric response in nanosheet-buffered lead zirconate titanate films on glass substrates.

Chopra A, Bayraktar M, Nijland M, Ten Elshof JE, Bijkerk F, Rijnders G.

Sci Rep. 2017 Mar 21;7(1):251. doi: 10.1038/s41598-017-00333-2.

35.

Treatment of initial parenchymal central nervous system involvement in systemic aggressive B-cell lymphoma.

Nijland M, Jansen A, Doorduijn JK, Enting RH, Bromberg JEC, Kluin-Nelemans HC.

Leuk Lymphoma. 2017 Sep;58(9):1-6. doi: 10.1080/10428194.2017.1285026. Epub 2017 Feb 6.

PMID:
28278731
36.

Primary Polyomavirus Infection, Not Reactivation, as the Cause of Trichodysplasia Spinulosa in Immunocompromised Patients.

van der Meijden E, Horváth B, Nijland M, de Vries K, Rácz EK, Diercks GF, de Weerd AE, Clahsen-van Groningen MC, van der Blij-de Brouwer CS, van der Zon AJ, Kroes ACM, Hedman K, van Kampen JJA, Riezebos-Brilman A, Feltkamp MCW.

J Infect Dis. 2017 Apr 1;215(7):1080-1084. doi: 10.1093/infdis/jiw403.

PMID:
27578847
37.

Epstein-Barr Virus-Positive Posttransplant Lymphoproliferative Disease After Solid Organ Transplantation: Pathogenesis, Clinical Manifestations, Diagnosis, and Management.

Nijland ML, Kersten MJ, Pals ST, Bemelman FJ, Ten Berge IJ.

Transplant Direct. 2015 Dec 15;2(1):e48. doi: 10.1097/TXD.0000000000000557. eCollection 2016 Jan.

38.

Efficacy of cisplatin-based immunochemotherapy plus alloSCT in high-risk chronic lymphocytic leukemia: final results of a prospective multicenter phase 2 HOVON study.

van Gelder M, van Oers MH, Alemayehu WG, Abrahamse-Testroote MC, Cornelissen JJ, Chamuleau ME, Zachée P, Hoogendoorn M, Nijland M, Petersen EJ, Beeker A, Timmers GJ, Verdonck L, Westerman M, de Weerdt O, Kater AP.

Bone Marrow Transplant. 2016 Jun;51(6):799-806. doi: 10.1038/bmt.2016.9. Epub 2016 Feb 15.

PMID:
26878656
39.

Proteomics Based Identification of Proteins with Deregulated Expression in B Cell Lymphomas.

Wu R, Nijland M, Rutgers B, Veenstra R, Langendonk M, van der Meeren LE, Kluin PM, Li G, Diepstra A, Chiu JF, van den Berg A, Visser L.

PLoS One. 2016 Jan 11;11(1):e0146624. doi: 10.1371/journal.pone.0146624. eCollection 2016.

40.

Maternal obesity disrupts the methionine cycle in baboon pregnancy.

Nathanielsz PW, Yan J, Green R, Nijland M, Miller JW, Wu G, McDonald TJ, Caudill MA.

Physiol Rep. 2015 Nov;3(11). pii: e12564. doi: 10.14814/phy2.12564.

41.

Reduced placental amino acid transport in response to maternal nutrient restriction in the baboon.

Pantham P, Rosario FJ, Nijland M, Cheung A, Nathanielsz PW, Powell TL, Galan HL, Li C, Jansson T.

Am J Physiol Regul Integr Comp Physiol. 2015 Oct;309(7):R740-6. doi: 10.1152/ajpregu.00161.2015. Epub 2015 Aug 5.

42.

Role of catecholamines in maternal-fetal stress transfer in sheep.

Rakers F, Bischoff S, Schiffner R, Haase M, Rupprecht S, Kiehntopf M, Kühn-Velten WN, Schubert H, Witte OW, Nijland MJ, Nathanielsz PW, Schwab M.

Am J Obstet Gynecol. 2015 Nov;213(5):684.e1-9. doi: 10.1016/j.ajog.2015.07.020. Epub 2015 Jul 26.

PMID:
26212181
43.

Back to the future: transgenerational transmission of xenobiotic-induced epigenetic remodeling.

Jiménez-Chillarón JC, Nijland MJ, Ascensão AA, Sardão VA, Magalhães J, Hitchler MJ, Domann FE, Oliveira PJ.

Epigenetics. 2015;10(4):259-73. doi: 10.1080/15592294.2015.1020267. Epub 2015 Mar 16. Review.

44.

Effects of moderate global maternal nutrient reduction on fetal baboon renal mitochondrial gene expression at 0.9 gestation.

Pereira SP, Oliveira PJ, Tavares LC, Moreno AJ, Cox LA, Nathanielsz PW, Nijland MJ.

Am J Physiol Renal Physiol. 2015 Jun 1;308(11):F1217-28. doi: 10.1152/ajprenal.00419.2014. Epub 2015 Mar 11.

45.

Atomically defined templates for epitaxial growth of complex oxide thin films.

Dral AP, Dubbink D, Nijland M, ten Elshof JE, Rijnders G, Koster G.

J Vis Exp. 2014 Dec 4;(94). doi: 10.3791/52209.

46.

The mutational landscape of Hodgkin lymphoma cell lines determined by whole-exome sequencing.

Liu Y, Abdul Razak FR, Terpstra M, Chan FC, Saber A, Nijland M, van Imhoff G, Visser L, Gascoyne R, Steidl C, Kluiver J, Diepstra A, Kok K, van den Berg A.

Leukemia. 2014 Nov;28(11):2248-51. doi: 10.1038/leu.2014.201. Epub 2014 Jun 20. No abstract available.

PMID:
24947018
47.

Improved Langmuir-Blodgett titanate films via in situ exfoliation study and optimization of deposition parameters.

Yuan H, Lubbers R, Besselink R, Nijland M, Ten Elshof JE.

ACS Appl Mater Interfaces. 2014 Jun 11;6(11):8567-74. doi: 10.1021/am501380d. Epub 2014 May 21.

PMID:
24819117
48.

Local control over nucleation of epitaxial thin films by seed layers of inorganic nanosheets.

Nijland M, Kumar S, Lubbers R, Blank DH, Rijnders G, Koster G, ten Elshof JE.

ACS Appl Mater Interfaces. 2014 Feb 26;6(4):2777-85. doi: 10.1021/am4052624. Epub 2014 Feb 5.

PMID:
24467475
49.

Liver mTOR controls IGF-I bioavailability by regulation of protein kinase CK2 and IGFBP-1 phosphorylation in fetal growth restriction.

Abu Shehab M, Damerill I, Shen T, Rosario FJ, Nijland M, Nathanielsz PW, Kamat A, Jansson T, Gupta MB.

Endocrinology. 2014 Apr;155(4):1327-39. doi: 10.1210/en.2013-1759. Epub 2014 Jan 17.

50.

Reply to KN Litwak and S Levin.

Keenan K, Bartlett TQ, Nijland M, Zürcher NR, Nathanielsz PW.

Am J Clin Nutr. 2014 Jan;99(1):211-2. doi: 10.3945/ajcn.113.075960. No abstract available.

Supplemental Content

Loading ...
Support Center